A phase III trial comparing platinum-doublet chemotherapy plus pembrolizumab with platinum-doublet chemotherapy was conducted in stage IV, non-squamous NSCLC patients with PS 0–1 and who did not have EGFR mutation or ALK rearrangement (KEYNOTE-189 study) [20]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.